Understanding the Various Considerations for EDC Selection
An Interview with Kathleen Boruchowski, Director of Data Management, Veristat
By Amanda Truesdale, MA, MBA, VP Biometrics
When database locks are delayed, or regulatory agencies request additional analyses for new drug applications (NDAs) or marketing authorization applications (MAAs), it seems there is no alternative but to take a hit to the timeline — or is there?